Study to Assess Changes in the Immune Profile in Adults With Early Rheumatoid Arthritis

August 19, 2020 updated by: Bristol-Myers Squibb

A Randomized, Head-to-Head, Single-Blinded Study to Assess Changes in the Immune Profile in Response to Treatment With Subcutaneous Abatacept in Combination With Methotrexate Versus Subcutaneous Adalimumab in Combination With Methotrexate in Adults With Early Rheumatoid Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs

The purpose of this study is to examine changes in immune cells and proteins in response to treatment with two approved therapies for Rheumatoid arthritis (RA), abatacept versus adalimumab, both given in combination with methotrexate.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

80

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Canada
    • Ontario
      • Toronto, Ontario, Canada, M9V 4B4
        • Dr. Anil K Gupta Med Prof Corp
      • Windsor, Ontario, Canada, N8X 5A6
        • Essex County Medical Society
    • Quebec
      • Montreal, Quebec, Canada, H2L 1S6
        • Institut de Rhumatologie de Montreal
      • Trois-rivieres, Quebec, Canada, G8Z 1Y2
        • Centre De Recherche Musculo-Squelettique
  • Mexico
      • Mexico D.F., Mexico, 06760
        • Clinica Integral en Osteoporosis y Artritis CLINOSAR Mexico S.A. de C.V.
    • Distrito Federal
      • Mexico City, Distrito Federal, Mexico, 11850
        • CINTRE - Centro de investigacion y tratamiento reumatologico, S.C.
    • Jalisco
      • Guadalajara, Jalisco, Mexico, 44650
        • Clinica de Investigacion en Reumatologia y Obesidad S.C.
  • United States
    • Alabama
      • Birmingham, Alabama, United States, 35294-7201
        • University of Alabama at Birmingham
      • Huntsville, Alabama, United States, 35801
        • Rheumatology Associates Of North Alabama, P.C.
      • Tuscaloosa, Alabama, United States, 35406
        • Clinical and Translational Research Center of Alabama, PC
    • Arizona
      • Glendale, Arizona, United States, 85306
        • Arizona Arthritis & Rheumatology Research PLLC
      • Phoenix, Arizona, United States, 85037
        • Arizona Arthritis & Rheumatology Research PLLC
    • California
      • Fullerton, California, United States, 92835
        • St. Joseph Heritage Medical Group
      • Palm Desert, California, United States, 92260
        • Desert Medical Advances
    • Colorado
      • Aurora, Colorado, United States, 80045
        • University of Colorado Health Sciences Center
    • District of Columbia
      • Washington, District of Columbia, United States, 20060
        • Howard University Hospital
      • Washington, District of Columbia, United States, 20037
        • Medical Faculty Associates,Inc.
    • Florida
      • Plantation, Florida, United States, 33324
        • Integral Rheumatology & Immunology Specialists
    • Georgia
      • Marietta, Georgia, United States, 30060
        • Marietta Rheumatology
    • Maryland
      • Wheaton, Maryland, United States, 20902
        • The Center for Rheumatology and Bone Research
    • Massachusetts
      • Worcester, Massachusetts, United States, 01605
        • Clinical Pharmacology Study Group
    • Michigan
      • Grand Blanc, Michigan, United States, 48439
        • Aa Mrc Llc
    • New Hampshire
      • Lebanon, New Hampshire, United States, 03756
        • Dartmouth-Hitchcock Medical Center
    • Oregon
      • Portland, Oregon, United States, 97239
        • Oregon Health & Science University (OHSU)
    • Pennsylvania
      • Duncansville, Pennsylvania, United States, 16635-8406
        • Altoona Center for Clinical Research
    • South Carolina
      • Myrtle Beach, South Carolina, United States, 29572
        • Carolina Health Specialists
    • Tennessee
      • Jackson, Tennessee, United States, 38305
        • West Tennessee Research Institute
    • Virginia
      • Arlington, Virginia, United States, 22205
        • Arthritis Clinic Of Northern Virginia, P.C.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

  • Symptoms of RA for no more than 12 months prior to enrollment
  • Meet American College of Rheumatology/European League against Rheumatism (ACR/EULAR) 2010 criteria for classification of RA
  • Treated with Methotrexate (MTX) for at least 12 weeks prior to randomization with a stable oral dose for at least 4 weeks, Subjects must randomize on the maximum tolerated dose of oral methotrexate (minimum of 15 mg and maximum of 25 mg per week), dose of MTX < 15 mg/week but ≥ 7.5 mg/week is permitted if subjects are intolerant to higher doses
  • At least 3 tender & 3 swollen joints
  • Anti-cyclic citrullinated peptide (CCP) > 3X the upper limit of normal and positive rheumatoid factor

Exclusion Criteria:

  • History of other autoimmune diseases (eg, psoriasis, systemic lupus, erythematosus, etc)
  • Prior use of non-biologic therapy other than methotrexate
  • Prior use of biologic and targeted synthetic disease-modifying anti-rheumatic drugs (DMARD) therapy
  • Subjects with chronic or recent acute serious infection

Other protocol defined inclusion/exclusion criteria could apply

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Treatment A
Abatacept Single Blind Treatment Period
Drug: Methotrexate
Drug: Abatacept
Other Names:
  • Orencia
Active Comparator: Treatment B
Adalimumab Single Blind Treatment Period
Drug: Methotrexate
Drug: Adalimumab
Other Names:
  • Humira
Drug: Abatacept
Other Names:
  • Orencia
Active Comparator: Treatment C
Abatacept Cumulative Treatment Period
Drug: Abatacept
Other Names:
  • Orencia

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Percentage of Adverse Events (AEs)
Time Frame: up to 85 days post last dose, approximately 40 weeks
Percentage of participants who experienced an AE
up to 85 days post last dose, approximately 40 weeks
Percentage of Participants With an Serious Adverse Events (SAEs)
Time Frame: up to 85 days post last dose, approximately 40 weeks
Percentage of participants who experienced an SAEs
up to 85 days post last dose, approximately 40 weeks
Percentage of Participants With Adverse Events Leading to Discontinuation (AEsDc)
Time Frame: up to 85 days post last dose, approximately 40 weeks
Percentage of participants who experienced an (AEsDc)
up to 85 days post last dose, approximately 40 weeks
Percentage of Serious Adverse Events Leading to Discontinuation (SAEsDc)
Time Frame: up to 85 days post last dose, approximately 40 weeks
Percentage of participants who experienced an (SAEsDc)
up to 85 days post last dose, approximately 40 weeks
Percentage of Drug Related Adverse Events (DRAEs)
Time Frame: up to 85 days post last dose, approximately 40 weeks
Percentage of participants who experienced an DRAEs
up to 85 days post last dose, approximately 40 weeks
Percentage of Drug Related Serious Adverse Events (DRSAEs)
Time Frame: up to 85 days post last dose, approximately 40 weeks
Percentage of participants who experienced an DRSAEs
up to 85 days post last dose, approximately 40 weeks
Number of Deaths
Time Frame: up to 85 days post last dose, approximately 40 weeks
Number of participants who experienced Death
up to 85 days post last dose, approximately 40 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Bristol-Myers Squibb

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 19, 2015

Primary Completion (Actual)

March 28, 2019

Study Completion (Actual)

March 28, 2019

Study Registration Dates

First Submitted

September 4, 2015

First Submitted That Met QC Criteria

September 22, 2015

First Posted (Estimate)

September 23, 2015

Study Record Updates

Last Update Posted (Actual)

September 3, 2020

Last Update Submitted That Met QC Criteria

August 19, 2020

Last Verified

August 1, 2020

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • IM101-567

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Rheumatoid Arthritis

Clinical Trials on Methotrexate

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Paraguay

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe